HOSPITAL UNIVERSITARIO RUBER

Departamento

Foto de HOSPITAL UNIVERSITARIO RUBER

Foto de Pedro

Pedro
Sánchez Rovira

Publicaciones en las que colabora con Pedro Sánchez Rovira (6)

2024

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
ESMO Open, Vol. 9, Núm. 10
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Breast, Vol. 77

2022

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
Cancers, Vol. 14, Núm. 23

2020

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530

2016

Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428